Skip navigation
|
Contact Us
[
Viewing Options
]
Search this site
Home
Hepatitis C
The Liver & Hepatitis C
Living with Hepatitis C
Treatment
Wellness
Support
Hepatitis C Trust
News
News
News
2009
2008
December
News From AASLD Liver Conference 2008
November
October
September
August
July
June
European commission approves shorter 16 week treatment for certain geno 2 and 3 patients
Vertex announces new trial of telaprevir in non responders
Vertex CEO preparing for 09 hepatitis drug launch
Very Early Response to Interferon-based Therapy for Hepatitis C Is Apparent within the First 24 Hours
Course of Chronic Hepatitis C in Children
Central Asia: World Bank Warns Of Tainted Blood Transfusions Across Region
Poly-MVA - The First Dietary Supplement To Be Cleared By The FDA For Use In A Cancer Study
For Patients with HCV Genotype 6 - 48 Weeks Treatment is Superior to 24 Weeks
Active and Recovering Injection Drug Users Can Benefit from Hepatitis C Treatment if They Maintain Good Adherence
Will Vertex seek regulatory approval for telaprevir in 2009?
Vertex reports on Prove 3 interim results
Herbal Product Stevioside Inhibits HCV Replication and Curcumin Suppresses Fibrogenic Cell Activity in Laboratory Studies
Last public hearing of independent public inquiry into Contaminated Blood and Blood Products
Selective hepatitis C screening for pregnant women isn't working
Tattoed Irish Should Be Tested for Hepatitis C
Mortality Due to Hepatitis C in the U.S.: Has the Worst Passed?
Eltrombopag Trial Results
Parliamentary Debate on Liver Disease
World Hepatitis Day News
May
April
March
February
January
2007
2006
2005
2004
Print this page
Email to a friend
Comment on this page
Link to this page
Add page to favourites
News
>
2008
>
June
>
Parliamentary Debate on Liver Disease
Parliamentary Debate on Liver Disease
Last updated:26June2008
Westminster Hall debates
Wednesday, 21 May 2008 - Liver Disease
Click Here
to read this debate
[
Sign In
]
[
Sign Up
]
